Roche gains expanded use of diagnostic tests to identify eligible Ziihera patients
Finance Desk
Rafael_Wiedenmeier/iStock Unreleased via Getty Images
The US FDA has expanded the use of Roche’s (RHHBY) PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH DNA Probe Cocktail companion diagnostics for to help identifymetastatic gastroesophageal adenocarcinoma patients that could benefit from Jazz Pharmaceuticals’ (JAZZ) Ziihera (zanidatamab).
